What question did this study set out to answer?

This research aims to characterize exceptional responders undergoing long-term PARP inhibitor therapy for recurrent ovarian cancer.

February 28, 2026Open Access

Characterization of exceptional responders with long-term PARP inhibitor therapy in recurrent ovarian cancer: an analysis of 23 patients from Charité

Key Points

This research aims to characterize exceptional responders undergoing long-term PARP inhibitor therapy for recurrent ovarian cancer.
Analysis of 23 patients from Charité
Clinical and genetic characterization of responders
Monitoring for adverse events and secondary malignancies
Exceptional responders exhibit heterogenic clinical and genetic traits
High rates of adverse events observed
Dose reductions required at various treatment points

Abstract

ExR-LTs present with heterogenic clinical and genetic characteristics. Clinical management is complex because of a high rate of AE and need of dose reductions at various points in time. Close monitoring for AE, recurrences and secondary malignancies must be carried out throughout the entire time of treatment.

Bookmark

View Full Paper

Cite This Study

Glajzer et al. (Thu,) studied this question.

synapsesocial.com/papers/69a2877b0a974eb0d3c032f1 https://doi.org/https://doi.org/10.1007/s00404-026-08309-2

Bookmark

View Full Paper